A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-18
DOI
10.1038/s41467-018-03537-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment
- (2017) Xiong Zou et al. EUROPEAN JOURNAL OF CANCER
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
- (2017) Stephen J Luen et al. LANCET ONCOLOGY
- EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
- (2017) Jan Van Deun et al. NATURE METHODS
- Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
- (2016) Huiping Li et al. Chinese Journal of Cancer Research
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
- (2016) Sen Guo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
- (2016) Marina Bagnoli et al. LANCET ONCOLOGY
- Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
- (2016) Chi Lam Au Yeung et al. Nature Communications
- Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab
- (2016) Sherene Loi et al. JAMA Oncology
- Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
- (2015) Xiaodan Meng et al. BRITISH JOURNAL OF CANCER
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer
- (2015) Keun Hur et al. JNCI-Journal of the National Cancer Institute
- A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study
- (2015) Xue-Jia Lin et al. LANCET ONCOLOGY
- Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer
- (2015) Keun Hur et al. JNCI-Journal of the National Cancer Institute
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
- (2014) Xingming Ye et al. BMB Reports
- Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
- (2014) Volkmar Müller et al. BREAST CANCER RESEARCH AND TREATMENT
- A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis
- (2014) Shicheng Su et al. CANCER CELL
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative and stoichiometric analysis of the microRNA content of exosomes
- (2014) J. R. Chevillet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic Cancer
- (2013) W.-S. Wang et al. Cancer Prevention Research
- Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
- (2013) R. Wei et al. CLINICAL CANCER RESEARCH
- MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma
- (2013) Rashmi S. Goswami et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer
- (2013) Yuji Toiyama et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
- (2013) Jia-Xing Zhang et al. LANCET ONCOLOGY
- Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity
- (2013) Jianhua Li et al. NATURE IMMUNOLOGY
- Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs
- (2013) Carolina Villarroya-Beltri et al. Nature Communications
- Cellular Heterogeneity and Molecular Evolution in Cancer
- (2012) Vanessa Almendro et al. Annual Review of Pathology-Mechanisms of Disease
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis
- (2012) Na Liu et al. LANCET ONCOLOGY
- Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
- (2011) C. C. Pritchard et al. Cancer Prevention Research
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
- (2011) H. Wong et al. ONCOLOGIST
- Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer
- (2011) Robert Mahn et al. UROLOGY
- Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
- (2010) B. C. Browne et al. ANNALS OF ONCOLOGY
- Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
- (2010) Helen M. Heneghan et al. ANNALS OF SURGERY
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non–Small-Cell Lung Cancer
- (2010) Zhibin Hu et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients WithHER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
- (2010) Vicente Valero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)
- (2010) Evan M. Kroh et al. METHODS
- Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
- (2010) J.-M. Extra et al. ONCOLOGIST
- Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
- (2009) Siân Lennon et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
- (2009) Tetsuya Ueda et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started